A. The dispensing pharmacist has a responsibility to validate every opiate prescription with the prescribing physician prior to dispensing. B. The dispensing pharmacist is responsible for annual correspondence with the Drug Enforcement Agency (DEA) regarding suspicious controlled substance dispensations. C. The responsibility for proper opiate prescribing and dispensing of controlled substances resides solely with the prescribing physician and the DEA. D. The responsibility for proper prescribing and dispensing of controlled substances rests upon both the prescribing practitioner and pharmacist who fills the prescription.

A. A large quantity of prescription opiates is written for a patient diagnosed with cancer-related pain. B. A prescriber that repeatedly initiates patients on high doses of opiates (eg, oxycodone ER 80 mg) C. The patient's address is a significant distance away from the dispensing pharmacy. D. The same combinations of controlled substances are prescribed by the same prescriber for multiple patients.

A. Fill out DEA form 106 (Report of Theft or Loss of Controlled Substances) B. Initiate the naloxone-access protocol C. Inform the local police D. Report it to the Prescription Drug Monitoring Program

A. A pharmacist cannot share information obtained through a PDMP with a physician due to HIPAA laws. B. The Center for Disease Control and Prevention's opiate prescribing guidelines recommend accessing the PDMP database for patients on chronic opioid therapy. C. All prescribers are required to consult their state's PDMP prior to writing a prescription for controlled substance. D. The PDMP allows users to see the medical indication for a controlled substance.

A. The CDC only recommends checking the Prescription Drug Monitoring Programs (PDMP) for short-term opiate therapy. B. The PDMP should be accessed annually for patients receiving chronic opiate therapy. C. At the initiation of opioid therapy for patients with chronic pain if the medication is being used for an off-label indication D. At the initiation of opioid therapy for patients with chronic pain, and periodically thereafter, during therapy, ranging from every prescription to every 3 months